Advantage of Prehospital Thrombolysis in Acute Coronary Syndrome
DOI:
https://doi.org/10.31150/ajshr.v3i2.907Keywords:
myocardial infarction, thrombolysis, fibrinolyticsAbstract
The review describes the features of thrombolytic therapy in patients with acute myocardial infarction in detail. Thrombolytic therapy helps to reduce 30-day mortality in myocardial infarction from 17-18% to 5-8%. The issues of the optimal period of thrombolysis from the onset of the clinical manifestations of a heart attack, alternative methods for restoring coronary blood flow, indications and contraindications, complications and side effects, and methods for evaluating the effectiveness of thrombolysis are highlighted. The main fibrin-selective and fibrin-non-selective fibrinolytic drugs: streptokinase, alteplase, tenecteplase are listed. The results of large randomized clinical trials on fibrinolytic therapy of myocardial infarction are presented. The possibilities of increasing the effectiveness and safety of fibrinolytics by combining them with acetylsalicylic acid and heparins are discussed.
References
Antman E.M. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients with ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines, for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee/ Antman E.M., Hand M., Armstrong P.W, [et al] // Circulation. - 2008. -Vol. 117. - P.296-329
Armstrong P., WEST Steering Committee. A comparison of pharmacologic therapy with/without timely coronary intervention vs. primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) study/ Armstrong P. // Eur Heart J. -2006. - Vol.27. -P.1530-1538.
Bjorklund E. Prehospital thrombolysis delivered by paramedics is associated with reduced time delay and mortality in ambulance-transported real-life patents with ST-elevation myocardial infarction / Bjorklund E., Stenestrand U., Lindback J., et al on behalf of the RIKS-HIA Investigators // Eur Heart J. - 2006. -Vol.27 - P.1146-1152.
Boersma E. Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction / Boersma E., the PCAT-2 Trialists' Collaborative Group //Eur Heart J. - 2006 - Vol.27 - P.779-788.
Danchin N. Comparison of thrombolysis followed by broad use of percutaneous coronary intervention with primary percutaneous coronary intervention for ST-segment-elevation acute myocardial infarction. Data from the French Registry on Acute ST-Elevation Myocardial Infarction (FAST-MI) / Danchin N., Coste P., Fejrieres J., [et al], for the FAST-MI Investigators. // Circulation. - 2008 - Vol.118 - P. 268276.
Eagle K.A. Global Registry of Acute Coronary Events (GRACE) InvestigatorsTrends in acute reperfusion therapy for ST-segment elevation myocardial infarction from 1999 to 2006: we are getting better but we have got a long way to go / Eagle K.A., Nallamothu B.K., Mehta R.H., [et al]. // Eur Heart J. - 2008.
Keeley E. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials / Keeley E., Boura J., Grines C. // Lancet. - 2003.-Vol.361 -P.13-20.
McNamara R. Effect of door-to-balloon time on mortality in patients with ST-segment elevation myocardial infarction / McNamara R., Wang Y., Herrin J., [et al], for the NRMI Investigators. // J Am CollCardiol. - 2006. - Vol.47 - P.45-51.
Morrison L. Mortality and prehospital thrombolysis for acute myocardial infarction. A meta-analysis / Morrison L., Verbeek P., McDonald A., [et al]. // JAMA. -Vol. 2000. -Vol.283 -P.2686-2692.
Nallamothu B. Times to treatment in transfer patients undergoing primary percutaneous coronary intervention in the United States. National Registry of Myocardial Infarction (NRMI)-3/4 Analysis / Nallamothu B., Bates E., Herrin J., [et al], for the NRMI Investigators. // Circulation. - 2005. - Vol.111 -P.761-767.
lmpact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty / Steg G., Bonnefoy E., Chabaud S., [et al], for the Comparison of Angioplasty Prehospital Thrombolysis In acute Myocardial infarction (CAPTIM) Investigators // Circulation. - 2003. -Vol.108 -P.2851-2856.
S.H.Pulatova .TROMBOLYTIC THERAPY IN ACUTE MYOCARDIAL INFARCTION// herald of emergency medicineю – 2019.- Vol.6.- P. 88-91.
Van de Werf F. The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation / Van de Werf F., Bax J., Betriu A., [et al]. //EHJ.- 2008. -Vol.29. -P.2909-2945.
Widimsky P. Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction. Final results of the randomized national multicentre trial—PRAGUE-2 / Widimsky P., Budesmsky T., Vorac D., [et al], on behalf of the PRAGUE Study Group Investigators // Eur Heart J. -2003. - Vol.24. - P.94-104.
